Landos Biopharma Probability of Future Stock Price Finishing Over 3.83

LABPDelisted Stock  USD 4.02  0.15  3.60%   
Landos Biopharma's future price is the expected price of Landos Biopharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Landos Biopharma performance during a given time horizon utilizing its historical volatility. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
  
Please specify Landos Biopharma's target price for which you would like Landos Biopharma odds to be computed.

Landos Biopharma Target Price Odds to finish over 3.83

The tendency of Landos Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 3.83  in 90 days
 4.02 90 days 3.83 
about 22.52
Based on a normal probability distribution, the odds of Landos Biopharma to stay above $ 3.83  in 90 days from now is about 22.52 (This Landos Biopharma probability density function shows the probability of Landos Stock to fall within a particular range of prices over 90 days) . Probability of Landos Biopharma price to stay between $ 3.83  and its current price of $4.02 at the end of the 90-day period is about 9.24 .
Given the investment horizon of 90 days Landos Biopharma has a beta of -0.17. This indicates as returns on the benchmark increase, returns on holding Landos Biopharma are expected to decrease at a much lower rate. During a bear market, however, Landos Biopharma is likely to outperform the market. Additionally Landos Biopharma has an alpha of 0.5551, implying that it can generate a 0.56 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Landos Biopharma Price Density   
       Price  

Predictive Modules for Landos Biopharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Landos Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
4.024.024.02
Details
Intrinsic
Valuation
LowRealHigh
3.213.214.42
Details
Naive
Forecast
LowNextHigh
4.134.134.13
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.193.864.52
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Landos Biopharma. Your research has to be compared to or analyzed against Landos Biopharma's peers to derive any actionable benefits. When done correctly, Landos Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Landos Biopharma.

Landos Biopharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Landos Biopharma is not an exception. The market had few large corrections towards the Landos Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Landos Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Landos Biopharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.56
β
Beta against Dow Jones-0.17
σ
Overall volatility
0.53
Ir
Information ratio 0.1

Landos Biopharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Landos Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Landos Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Landos Biopharma is not yet fully synchronised with the market data
Landos Biopharma has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (21.93 M) with profit before overhead, payroll, taxes, and interest of 18 M.
Landos Biopharma currently holds about 55.75 M in cash with (20.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.

Landos Biopharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Landos Stock often depends not only on the future outlook of the current and potential Landos Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Landos Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding6.3 M
Cash And Short Term Investments37.5 M

Landos Biopharma Technical Analysis

Landos Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Landos Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Landos Biopharma. In general, you should focus on analyzing Landos Stock price patterns and their correlations with different microeconomic environments and drivers.

Landos Biopharma Predictive Forecast Models

Landos Biopharma's time-series forecasting models is one of many Landos Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Landos Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Landos Biopharma

Checking the ongoing alerts about Landos Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Landos Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Landos Biopharma is not yet fully synchronised with the market data
Landos Biopharma has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (21.93 M) with profit before overhead, payroll, taxes, and interest of 18 M.
Landos Biopharma currently holds about 55.75 M in cash with (20.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Consideration for investing in Landos Stock

If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital